← All trials
NCT05321082
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 5, 2022
- Primary completion
- Nov 23, 2024
- Completion date
- Nov 30, 2024
- First posted
- Apr 11, 2022
- Last posted
- Dec 14, 2022
- Enrollment
- 1041
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boehringer IngelheimLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.